Calithera Biosciences, Inc.
CALA
$0.00
$0.00400.00%
OTC PK
| 12/31/2022 | 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -65.34% | -44.21% | -39.49% | -37.64% | -19.54% |
| Gross Profit | 65.34% | -34.14% | 21.00% | 37.64% | 19.54% |
| SG&A Expenses | -43.75% | -51.47% | -19.37% | -21.52% | -17.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -89.39% | -46.78% | -34.27% | -33.42% | 205.38% |
| Operating Income | 89.39% | 14.57% | 20.49% | 33.42% | -205.38% |
| Income Before Tax | 89.98% | 12.26% | 36.57% | 32.16% | -206.70% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 89.98% | 12.26% | 36.57% | 32.16% | -206.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 89.98% | 12.26% | 36.57% | 32.16% | -206.70% |
| EBIT | 89.39% | 14.57% | 20.49% | 33.42% | -205.38% |
| EBITDA | 89.47% | 14.59% | 20.53% | 33.50% | -206.20% |
| EPS Basic | 92.28% | 33.17% | 142.15% | 43.77% | -188.56% |
| Normalized Basic EPS | 92.28% | 33.17% | 51.70% | 38.72% | -188.56% |
| EPS Diluted | 92.28% | 33.17% | 58.79% | 43.77% | -188.56% |
| Normalized Diluted EPS | 92.28% | 33.17% | 58.79% | 38.72% | -188.56% |
| Average Basic Shares Outstanding | 29.82% | 31.27% | 31.33% | 8.76% | 6.29% |
| Average Diluted Shares Outstanding | 29.82% | 31.27% | 53.90% | 8.76% | 6.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |